Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
2.045
-0.175 (-7.89%)
Nov 21, 2024, 1:59 PM EST - Market open
Company Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs.
The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC.
It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005.
Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Mersana Therapeutics, Inc.
| Country | United States |
| Founded | 2001 |
| IPO Date | Jun 28, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 123 |
| CEO | Martin Huber |
Contact Details
Address: 840 Memorial Drive Cambridge, Massachusetts 02139 United States | |
| Phone | 617 498 0020 |
| Website | mersana.com |
Stock Details
| Ticker Symbol | MRSN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001442836 |
| CUSIP Number | 59045L106 |
| ISIN Number | US59045L1061 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Martin H. Huber M.D. | President, Chief Executive Officer and Director |
| Brian C. DeSchuytner | Senior Vice President, Chief Financial Officer and Chief Operating Officer |
| Dr. Timothy B. Lowinger Ph.D. | Senior Vice President and Chief Science and Technology Officer |
| Alejandra Veronica Carvajal J.D. | Senior Vice President, Secretary and Chief Legal Officer |
| Mohan Bala Ph.D. | Senior Vice President and Chief Development Officer |
| Mikhail Papisov Ph.D. | Co-Founder |
| Ashish Mandelia | Chief Accounting Officer |
| Jason Fredette | Senior Vice President of Investor Relations and Corporate Communications |
| Chuck Miller | Senior Vice President of Regulatory Affairs |
| Marc Damelin | Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery and Develop. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 144 | Filing |
| Oct 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 7, 2024 | 144 | Filing |
| Oct 7, 2024 | 144 | Filing |
| Oct 7, 2024 | 144 | Filing |